NextCell Pharma AB (NXTCL.ST)
SEK 1.16
(1.22%)
SEK 1.16
(1.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -46.79 Million SEK | 6.47% |
| 2023 | -50.02 Million SEK | 48.49% |
| 2022 | -97.11 Million SEK | 30.22% |
| 2021 | -139.16 Million SEK | -533.78% |
| 2020 | -21.95 Million SEK | -9.09% |
| 2019 | -20.12 Million SEK | -545.99% |
| 2018 | -3.11 Million SEK | 81.23% |
| 2017 | -16.6 Million SEK | -183.82% |
| 2016 | -5.84 Million SEK | 32.8% |
| 2015 | -8.7 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -46.79 Million SEK | -124.98% |
| 2024 Q3 | -20.79 Million SEK | 31.57% |
| 2024 Q2 | -30.39 Million SEK | 24.82% |
| 2024 Q1 | -40.42 Million SEK | 19.18% |
| 2023 Q3 | -63.22 Million SEK | 18.54% |
| 2023 Q2 | -77.61 Million SEK | 12.06% |
| 2023 FY | -50.02 Million SEK | 48.49% |
| 2023 Q4 | -50.02 Million SEK | 20.88% |
| 2023 Q1 | -88.25 Million SEK | 9.12% |
| 2022 Q1 | -133.46 Million SEK | 4.1% |
| 2022 Q2 | -118.16 Million SEK | 11.46% |
| 2022 Q3 | -107.05 Million SEK | 9.41% |
| 2022 Q4 | -97.11 Million SEK | 9.28% |
| 2022 FY | -97.11 Million SEK | 30.22% |
| 2021 Q1 | -16.81 Million SEK | 23.44% |
| 2021 FY | -139.16 Million SEK | -533.78% |
| 2021 Q4 | -139.16 Million SEK | 7.69% |
| 2021 Q3 | -150.75 Million SEK | -1.22% |
| 2021 Q2 | -148.93 Million SEK | -785.99% |
| 2020 Q1 | -15.71 Million SEK | 21.92% |
| 2020 FY | -21.95 Million SEK | -9.09% |
| 2020 Q4 | -21.95 Million SEK | -291.21% |
| 2020 Q3 | -5.61 Million SEK | 47.55% |
| 2020 Q2 | -10.7 Million SEK | 31.91% |
| 2019 Q2 | -6.88 Million SEK | 34.02% |
| 2019 FY | -20.12 Million SEK | -545.99% |
| 2019 Q4 | -20.12 Million SEK | -794.95% |
| 2019 Q3 | -2.24 Million SEK | 67.34% |
| 2019 Q1 | -10.43 Million SEK | -234.97% |
| 2018 Q4 | -3.11 Million SEK | 47.45% |
| 2018 FY | -3.11 Million SEK | 81.23% |
| 2018 Q1 | -13.36 Million SEK | 19.49% |
| 2018 Q3 | -5.92 Million SEK | 37.22% |
| 2018 Q2 | -9.44 Million SEK | 29.34% |
| 2017 Q2 | -4.12 Million SEK | -170.51% |
| 2017 FY | -16.6 Million SEK | -183.82% |
| 2017 Q1 | 5.84 Million SEK | 200.0% |
| 2017 Q3 | -6.55 Million SEK | -59.03% |
| 2017 Q4 | -16.6 Million SEK | -153.11% |
| 2016 FY | -5.84 Million SEK | 32.8% |
| 2016 Q4 | -5.84 Million SEK | 0.0% |
| 2016 Q1 | 8.7 Million SEK | 0.0% |
| 2015 FY | -8.7 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -2.16 Million SEK | -2065.23% |
| BioArctic AB (publ) | -606.58 Million SEK | 92.286% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -145.491% |
| CombiGene AB (publ) | -101.44 Million SEK | 53.874% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 42.998% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -59.244% |
| OncoZenge AB (publ) | -12.62 Million SEK | -270.56% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 6.458% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 966.493% |
| Mendus AB (publ) | -96.29 Million SEK | 51.409% |
| LIDDS AB (publ) | -13.51 Million SEK | -246.289% |
| Lipum AB (publ) | -8.46 Million SEK | -452.754% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 187.914% |
| Simris Alg AB (publ) | 85.07 Million SEK | 154.999% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -3.48% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -253.692% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 128.174% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 63.867% |
| Ziccum AB (publ) | -2.13 Million SEK | -2089.547% |
| AcouSort AB (publ) | -23.98 Million SEK | -95.075% |
| Active Biotech AB (publ) | -33.2 Million SEK | -40.936% |
| Alzinova AB (publ) | -21.22 Million SEK | -120.44% |
| Amniotics AB (publ) | -5.63 Million SEK | -730.799% |
| Camurus AB (publ) | -1.16 Billion SEK | 95.985% |
| Cantargia AB (publ) | -139.74 Million SEK | 66.518% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -4969.406% |
| Genovis AB (publ.) | -43.94 Million SEK | -6.485% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 44.125% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 66.13% |
| Intervacc AB (publ) | -88.16 Million SEK | 46.925% |
| Kancera AB (publ) | -45.69 Million SEK | -2.404% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 43.078% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -46.555% |
| Saniona AB (publ) | 40.44 Million SEK | 215.684% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 85.975% |
| Xintela AB (publ) | -7.8 Million SEK | -499.188% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 6.295% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 328.136% |
| Corline Biomedical AB | -17.01 Million SEK | -175.045% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 44.126% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -18.812% |
| Aptahem AB (publ) | 2.9 Million SEK | 1708.676% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 85.781% |
| Fluicell AB (publ) | -2.76 Million SEK | -1593.471% |
| Biovica International AB (publ) | -58.73 Million SEK | 20.339% |
| Abliva AB (publ) | -57.24 Million SEK | 18.255% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 75.968% |
| 2cureX AB (publ) | -13.4 Million SEK | -249.106% |
| I-Tech AB | -83.26 Million SEK | 43.803% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 134.735% |
| Cyxone AB (publ) | -16.67 Million SEK | -180.688% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 16.275% |
| Biosergen AB | -1.88 Million SEK | -2384.897% |
| Nanologica AB (publ) | -9.38 Million SEK | -398.409% |
| SynAct Pharma AB | -61.75 Million SEK | 24.236% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -118.495% |
| BioInvent International AB (publ) | -236.3 Million SEK | 80.199% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 30.08% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -803.133% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -125.031% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1474.381% |